Skip to main content
. Author manuscript; available in PMC: 2021 Dec 1.
Published in final edited form as: Infect Dis Clin North Am. 2020 Sep 30;34(4):773–819. doi: 10.1016/j.idc.2020.05.001

Table 3.

Clinical indications for the use of ceftazidime-avibactam

Indication Indicated Bacteria Patient Population
cIAI (with metronidazole) E coli, K pneumoniae, Proteus mirabilis, Enterobacter cloacae, K oxytoca, C freundii complex, and P aeruginosa Adult and pediatric (≥3 mo) RECLAIM 1 and 287
NCT01499290
NCT01500239
REPRISE88
NCT01644643
NCT0247573389
cUTI, including pyelonephritis E coli, K pneumoniae, Enterobacter cloacae, C freundii complex, Proteus mirabilis, and P aeruginosa Adult and pediatric (≥3 mo) RECAPTURE90
NCT01595438
NCT01599806
REPRISE88
NCT01644643
NCT02497781
HABP/VABP K pneumoniae, Enterobacter cloacae, E coli, S marcescens, Proteus mirabilis, P aeruginosa, and Haemophilus influenzae Adult REPROVE91
NCT0180809292

Data from Allergan USA, Inc. AVYCAZ (Ceftazidime and Avibactam) for Injection, for Intravenous Use. Madison, NJ 07940 USA.; 2019.